Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2025-08-12 Interim / Quarterly Rep…
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report filed with the SEC for the quarterly period ended June 30, 2025. It includes detailed financial statements such as balance sheets, statements of operations, cash flows, notes to financial statements, management's discussion and analysis, risk factors, legal proceedings, and other required disclosures. The document is lengthy (15,000 characters) and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-08-12 English
4
Director's Dealing
2025-07-02 English
Director's Dealing 2025
Director's Dealing
2025-07-02 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 26, 2025. It primarily announces the posting of an updated corporate presentation on the company's investor relations website and furnishes the presentation as an exhibit. The text explicitly states that the presentation is furnished as Exhibit 99.1 and is incorporated by reference, and the document itself does not contain detailed financial data or analysis. The document length is 3476 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the investor presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2025-06-26 English
Director's Dealing 2025
Director's Dealing
2025-06-25 English
Director's Dealing 2025
Director's Dealing
2025-06-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.